Grimes & Company
ADMA icon

Grimes & Company’s ADMA Biologics ADMA Stock Holding History

Grimes & Company’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$118K Hold
11,805
– – ﹤0.01% 456
2026
Q2 		$98.8K Hold
11,805
– – ﹤0.01% 443
2026
Q1 		$106K Sell
11,805
-1,642
-12% -$25.9K ﹤0.01% 425
2025
Q4 		$245K Sell
13,447
-227
-2% -$3.83K 0.01% 405
2025
Q3 		$200K Hold
13,674
– – ﹤0.01% 440
2025
Q2 		$249K Sell
13,674
-8,016
-37% -$163K 0.01% 365
2025
Q1 		$430K Sell
21,690
-1,122
-5% -$19.4K 0.01% 251
2024
Q4 		$391K Sell
22,812
-473
-2% -$8.9K 0.01% 277
2024
Q3 		$465K Sell
23,285
-16,702
-42% -$260K 0.01% 242
2024
Q2 		$447K Sell
39,987
-5,280
-12% -$44.3K 0.01% 231
2024
Q1 		$299K Hold
45,267
– – 0.01% 271
2023
Q4 		$205K Hold
45,267
– – 0.01% 303
2023
Q3 		$162K Hold
45,267
– – 0.01% 283
2023
Q2 		$167K Hold
45,267
– – 0.01% 288
2023
Q1 		$150K Sell
45,267
-8,047
-15% -$27.8K 0.01% 278
2022
Q4 		$207K Hold
53,314
– – 0.01% 267
2022
Q3 		$130K Hold
53,314
– – 0.01% 261
2022
Q2 		$106K Hold
53,314
– – 0.01% 266
2022
Q1 		$98K Sell
53,314
-872
-2% -$1.36K 0.01% 293
2021
Q4 		$76K Hold
54,186
– – ﹤0.01% 294
2021
Q3 		$61K Hold
54,186
– – ﹤0.01% 298
2021
Q2 		$87K Buy
54,186
+3,116
+6% +$5.48K ﹤0.01% 297
2021
Q1 		$90K Buy
51,070
+15,761
+45% +$36.1K ﹤0.01% 276
2020
Q4 		$69K Buy
35,309
+1,809
+5% +$3.8K ﹤0.01% 264
2020
Q3 		$80K Buy
+33,500
New +$91.9K 0.01% 244

Other funds holding ADMA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Grimes & Company's ADMA Position: Q3 2026 in Review

Grimes & Company held its ADMA Biologics (ADMA) position steady in Q3 2026 at 11,805 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #456.

Grimes & Company first reported a position in ADMA in Q3 2020 and has held it in 25 quarters since. The position peaked at $465K in Q3 2024. 262 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Grimes & Company held 11,805 shares of ADMA Biologics worth $118K as of Q3 2026.
  • Grimes & Company left its ADMA Biologics share count unchanged in Q3 2026.
  • ADMA Biologics made up ﹤0.01% of Grimes & Company's portfolio in Q3 2026, its #456 holding.
  • Grimes & Company first reported a position in ADMA Biologics in Q3 2020 and has held it in 25 quarters since.
  • Grimes & Company's ADMA Biologics position peaked at $465K in Q3 2024.
  • 262 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Grimes & Company's 13F filing for Q3 2026, filed 29 Oct 2026.